Related Experiment Video

Updated: Jun 23, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

[Guideline development for MRD diagnostics in AML as a blueprint for solid tumors].

Michael Heuser1, Claudia Wickenhauser2, Leonie Oevel2

  • 1Klinik für Innere Medizin 4, Hämatologie und Onkologie, Universitätsmedizin Halle (Saale), Ernst-Grube-Straße 40, 06120, Halle, Deutschland. michael.heuser@uk-halle.de.

Pathologie (Heidelberg, Germany)
|June 22, 2026
PubMed
Summary

Measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML) has advanced significantly, with European LeukemiaNet (ELN) recommendations guiding clinical practice. These standards now inform cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) strategies in solid tumors.

Keywords:
Acute myeloid leukemiaClinical decision-makingHigh-throughput next-generation sequencingReference standardsRisk assesment

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Related Concept Videos